ZTS Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$94.43median target· current $79.38 (+19.0%)17 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
12 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio13.06Forward 11.99
EPS (TTM)$6.081.2% YoY
Profit margin27.7%HEALTHCARE
Market cap$32.80BLarge cap
Valuation
- Forward P/E
- 11.99
- PEG ratio
- 6.66
- P/B
- 9.40
- P/S (TTM)
- 3.44
- EV/EBITDA
- 9.25
Profitability & growth
- ROE (TTM)
- 64.9%
- Operating margin
- 40.7%
- Revenue growth YoY
- -0.2%
- Dividend yield
- 2.6%
- Beta
- 0.74
Last earnings
Aug 6, 2026 · Estimate $1.84 · Reported $1.87
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Zoetis Inc
Company profileZoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Classification
- Sector
- Healthcare
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 10 SYLVAN WAY, PARSIPPANY, NJ
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$32.80B
Shares outstanding$413.2M
52W high$145.51
52W low$68.77
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent